398 related articles for article (PubMed ID: 25498968)
1. Molecular mechanisms of the microsomal mixed function oxidases and biological and pathological implications.
Cederbaum AI
Redox Biol; 2015; 4():60-73. PubMed ID: 25498968
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Zanger UM; Schwab M
Pharmacol Ther; 2013 Apr; 138(1):103-41. PubMed ID: 23333322
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy.
Hu L; Zhuo W; He YJ; Zhou HH; Fan L
Pharmacogenet Genomics; 2012 Nov; 22(11):812-9. PubMed ID: 23047293
[TBL] [Abstract][Full Text] [Related]
4. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity.
Hart SN; Zhong XB
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):439-52. PubMed ID: 18433346
[TBL] [Abstract][Full Text] [Related]
5. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase.
Gu J; Weng Y; Zhang QY; Cui H; Behr M; Wu L; Yang W; Zhang L; Ding X
J Biol Chem; 2003 Jul; 278(28):25895-901. PubMed ID: 12697746
[TBL] [Abstract][Full Text] [Related]
6. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
[TBL] [Abstract][Full Text] [Related]
7. Denitrosation of the anti-cancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea catalyzed by microsomal glutathione S-transferase and cytochrome P450 monooxygenases.
Weber GF; Waxman DJ
Arch Biochem Biophys; 1993 Dec; 307(2):369-78. PubMed ID: 8274024
[TBL] [Abstract][Full Text] [Related]
8. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
[TBL] [Abstract][Full Text] [Related]
9. The versatility of the fungal cytochrome P450 monooxygenase system is instrumental in xenobiotic detoxification.
Lah L; Podobnik B; Novak M; Korošec B; Berne S; Vogelsang M; Kraševec N; Zupanec N; Stojan J; Bohlmann J; Komel R
Mol Microbiol; 2011 Sep; 81(5):1374-89. PubMed ID: 21810122
[TBL] [Abstract][Full Text] [Related]
10. The functional effects of physical interactions involving cytochromes P450: putative mechanisms of action and the extent of these effects in biological membranes.
Reed JR; Backes WL
Drug Metab Rev; 2016 Aug; 48(3):453-69. PubMed ID: 27500687
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of male-specific cytochrome P450s 2C11 and 3A2 in bile duct-ligated male rats: importance to reduced hepatic content of cytochrome P450 in cholestasis.
Chen J; Murray M; Liddle C; Jiang XM; Farrell GC
Hepatology; 1995 Aug; 22(2):580-7. PubMed ID: 7635428
[TBL] [Abstract][Full Text] [Related]
12. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
13. Drug metabolizing enzyme expression in rat choroid plexus: effects of in vivo xenobiotics treatment.
Gradinaru D; Minn AL; Artur Y; Minn A; Heydel JM
Arch Toxicol; 2009 Jun; 83(6):581-6. PubMed ID: 19023562
[TBL] [Abstract][Full Text] [Related]
14. Purification of catalytically active hepatic NADPH cytochrome P450 oxidoreductase from the rhesus monkey, Macaca mulatta.
Ramana KV; Kohli KK
Indian J Exp Biol; 1998 Oct; 36(10):960-6. PubMed ID: 10356957
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 Structure, Function and Clinical Significance: A Review.
Manikandan P; Nagini S
Curr Drug Targets; 2018; 19(1):38-54. PubMed ID: 28124606
[TBL] [Abstract][Full Text] [Related]
16. Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily.
Skarydová L; Wsól V
Drug Metab Rev; 2012 May; 44(2):173-91. PubMed ID: 22181347
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase.
Henderson CJ; Otto DM; Carrie D; Magnuson MA; McLaren AW; Rosewell I; Wolf CR
J Biol Chem; 2003 Apr; 278(15):13480-6. PubMed ID: 12566435
[TBL] [Abstract][Full Text] [Related]
18. Drug-metabolizing enzymes: mechanisms and functions.
Sheweita SA
Curr Drug Metab; 2000 Sep; 1(2):107-32. PubMed ID: 11465078
[TBL] [Abstract][Full Text] [Related]
19. Non-specific inhibition of human cytochrome P450-catalyzed reactions by hemin.
Kim EY; Kim JS; Kim MY; Koh WS; Guengerich FP; Yun CH
Toxicol Lett; 2004 Nov; 153(2):239-46. PubMed ID: 15451555
[TBL] [Abstract][Full Text] [Related]
20. Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.
Shaw PM; Hosea NA; Thompson DV; Lenius JM; Guengerich FP
Arch Biochem Biophys; 1997 Dec; 348(1):107-15. PubMed ID: 9390180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
